Vimarsana
Biggest News Aggregation in the World

Page 12 - Controlled Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Controlled Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Controlled Trials Today - Breaking & Trending Today

B-mode transorbital ultrasonography for the diagnosis of idiopathic intracranial hypertension: an updated systematic review and meta-analysis. - Vimarsana News

B-mode transorbital ultrasonography for the diagnosis of idiopathic intracranial hypertension: an updated systematic review and meta-analysis.

This systematic review and meta-analysis aimed to evaluate the role of B-mode transorbital ultrasonography (TOS) for the diagnosis of idiopathic intracranial hypertension (IIH) in adults.MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) (1966-May 2022) were searched to identify studies reporting ultrasonographic data about the optic nerve sheath diameter (ONSD) and optic disc elevation

Study finds blue-light glasses don't help with eye strain - Vimarsana News

Study finds blue-light glasses don't help with eye strain

Blue-light “blocking” or filtering eyeglasses may not be easing your eye strain from computer use or improving your sleep.

Source: ksat.com
Type 2 Diabetes Increases Risk for Hepatic Decompensation, HCC in NAFLD - Vimarsana News

Type 2 Diabetes Increases Risk for Hepatic Decompensation, HCC in NAFLD

The likelihood of developing hepatic decompensation and hepatocellular carcinoma is higher among patients with NAFLD and type 2 diabetes.

Somnolence, Insomnia Risk Higher With Antidepressant Use Compared With Placebo - Vimarsana News

Somnolence, Insomnia Risk Higher With Antidepressant Use Compared With Placebo

The risk for sleep disturbances, including somnolence and insomnia, is an adverse event associated with antidepressant use.

Post-viral olfactory loss and parosmia - Vimarsana News

Post-viral olfactory loss and parosmia

The emergence of SARS-CoV-2 has brought olfactory dysfunction to the forefront of public awareness, because up to half of infected individuals could develop olfactory dysfunction. Loss of smell—which can be partial or total—in itself is debilitating, but the distortion of sense of smell (parosmia) that can occur as a consequence of a viral upper respiratory tract infection (either alongside a reduction in sense of smell or as a solo symptom) can be very distressing for patients. Incidence of olfactory loss after SARS-CoV-2 infection has been estimated by meta-analysis to be around 50%, wit...

Source: bmj.com